Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
MENLO PARK, Calif., Sept. 28, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that company executives will present at upcoming conferences in October.
| Event: | Cell & Gene Meeting on the Mesa | ||
| Date: | October 5, 2017 | ||
| Time: | 2:15 – 2:30 p.m. PT | ||
| Location: | La Jolla, CA | ||
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | ||
| Event: | Chardan Gene Therapy Conference | ||
| Date: | October 10, 2017 | ||
| Time: | 2:00 – 2:25 p.m. ET | ||
| Location: | New York, NY | ||
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | ||
| Event: | Jefferies Gene Technology Summit Conference | ||
| Date: | October 12, 2017 | ||
| Location: | New York, NY | ||
| Panel: | Mehdi Gasmi, Ph.D., chief science and technology officer |
A live and replay video webcast of the Cell & Gene Meeting on the Mesa may be accessed by visiting www.meetingonthemesa.com/webcast/.
A live and replay audio webcast of the Chardan Gene Therapy Conference fireside chat will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Contact: Charles Butler Vice President, Investor Relations & Corporate Communications 650-272-6260 [email protected]
